Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine said today that the US Food and Drug Administration has granted Breakthrough Device designation to a new liquid biopsy assay the firm is developing, an expanded version of its existing FoundationACT assay.

Under the Breakthrough Device program, an expansion of the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Jul
23

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients.